Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-Blind Study of Pentavalent HPV L1 VLP Vaccine With Concomitant Gardasil in Young Women
2007-003852-13Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2007
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of V505 in human papillomavirus infection, Cervical Cancer (CC), Vulval carcinoma and 4 more, sponsored by Merck & Co. Primary endpoints: Safety and tolerability: severe injection-site reactions, Safety and tolerability: vaccine-related serious adverse experiences and 1 more. Started Sep 2007; status: completed.
02
Drugs
V505
03
Conditions
human papillomavirus infectionCervical Cancer (CC)Vulval carcinomavaginal cancercervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on 2007-003852-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003852-13.